# A Phase III Randomized, Modified Double-blind, Multi-centric, Comparative Study, to Evaluate the Non-inferiority of Immunogenicity and Safety of Hillchol® (BBV131)to Shanchol™ Along With Lot-to-lot Consistency of Hillchol®(BBV131).

> **NCT05507229** · PHASE3 · UNKNOWN · sponsor: **Bharat Biotech International Limited** · enrollment: 1800 (actual)

## Conditions studied

- Cholera

## Interventions

- **BIOLOGICAL:** Hillchol vaccine
- **BIOLOGICAL:** Shanchol Vaccine

## Key facts

- **NCT ID:** NCT05507229
- **Lead sponsor:** Bharat Biotech International Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-22
- **Primary completion:** 2022-07-30
- **Final completion:** 2022-10-30
- **Target enrollment:** 1800 (ACTUAL)
- **Last updated:** 2022-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05507229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05507229, "A Phase III Randomized, Modified Double-blind, Multi-centric, Comparative Study, to Evaluate the Non-inferiority of Immunogenicity and Safety of Hillchol® (BBV131)to Shanchol™ Along With Lot-to-lot Consistency of Hillchol®(BBV131).". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05507229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*